Sharemaestro Newsreel

TherapeuticsMD: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for TherapeuticsMD. However, the content of the article is empty, indicating that specific financial details were not included or were unavailable at the time of extraction.

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

Collegium Pharmaceutical's Q2 earnings showed sales growth driven by its ADHD business, with Jornay PM revenue up 41% year-over-year, but overall revenue missed Wall Street estimates due to pricing pressure on the NUCYNTA pain franchise. Despite this, the company raised its full-year revenue guidance. …

Aquestive Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Aquestive Therapeutics, Inc.? Here are five stocks we like better. Aquestive plans to resubmit Anaphylm's FDA application before the end of Q3 after revised packaging and instructions substantially reduced pouch-opening, film-tearing and administration errors in validation studies. Management is assuming …

Perrigo (PRGO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Interim President and Chief Executive Officer - Albert Manzone Executive Vice President and Chief Financial Officer - Eduardo Bezerra VP Global Investor Relations - Eric Jacobson Full Conference …

Earnings call transcript: Liquidia misses EPS in Q2 2026 as YUTREPIA sales surge

Liquidia Corporation reported a Q2 2026 earnings miss with EPS of $0.74 against an estimated $0.76, but surpassed revenue expectations with $171.6

Earnings call transcript: Kamada tops Q2 2026 estimates as growth stays steady

Kamada Ltd. reported record-high Q2 2026 results, surpassing Wall Street expectations with $0.16 EPS on $54.9 million revenue. The company achieved 23% year-over-year revenue growth and a 29% increase in adjusted EBITDA, driven by strong performance across its specialty plasma-derived products and disciplined expense …

Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026

Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Kamada earnings beat by $0.04, revenue topped estimates

Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings

Emergent BioSolutions' Executive Vice President and Chief Growth Officer, Stephanie Duatschek, has reported her initial equity holdings, which include 197,416 shares of common stock and various employee stock options. Her holdings comprise 55,639 direct common shares and 141,777 unvested Restricted Stock Units (RSUs), with …

IQV Stock Gains 42% in 3 Months: Here's What You Should Know

IQVIA Holdings Inc. IQV stock has rallied over the past three months. The company's shares have jumped 41.5%, outperforming the industry's 17.2% growth and the Zacks S&P 500 Composite's 3.4% uptick. 3-Month Share Price PerformanceZacks Investment Research Image Source: Zacks Investment Research Let us …

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates

Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock.

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals Inc. (NASDAQ:ANIP), sold 3,162 shares of common stock for $243,474 on August 10, 2026. Following the sale, Gutwerg directly holds 75,534 shares. This transaction comes as the company's stock trades near its 52-week low, and after …

Amphastar CFO William Peters sells $183,886 in company stock

Amphastar Pharmaceuticals CFO William J. Peters sold 8,180 shares of company stock for $183,886 on August 7, 2026, as part of a Rule 10b5-1 trading plan. Concurrently, he acquired 5,053 shares through employee stock option exercises for $99,998. Following these transactions, Peters beneficially owns …

Form 8K Citius Oncology Inc For: 12 August By Investing.com

This article announces the filing of a Form 8K by Citius Oncology Inc. on August 12, 2026. The content is brief and primarily serves as a news alert for the filing, with a focus on market data and other news. Citius Oncology Inc. (CTOR) …

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com

Citius Oncology, Inc. has appointed Jonathan Peri, Ph.D., J.D., as an independent director to its board, expanding it to nine members. Peri brings 30 years of experience in higher education, financial services, law, and corporate governance. The company, a subsidiary of Citius Pharmaceuticals, Inc., …

Curaleaf to take offer directly to shareholders in bid to buy Edmonton-based Aurora Cannabis

Curaleaf Holdings Inc. is making a direct appeal to Aurora Cannabis shareholders after its acquisition attempts were rebuffed by Aurora's board. Curaleaf is proposing to pay $4 US per share plus $0.75 US cash for each Aurora share, a move Aurora's board has resisted, …

Haleon slides Wednesday, underperforms market

Haleon PLC (HLN) shares dropped 1.51% to £3.60 on Wednesday, underperforming the broader market as the FTSE 100 Index (UKX) also fell by 0.10%. The company's stock closed significantly below its 52-week high of £4.16, which was reached in February.

Elanco (ELAN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jeffrey SimmonsChief Financial Officer - Bob VanHimbergenVice President of Investor Relations and ESG - Tiffany KanagaInvestor Relations - Beth Haney TAKEAWAYS Total …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

Earnings Release: Here's Why Analysts Cut Their Canopy Growth Corporation (TSE:WEED) Price Target To CA$2.02

Canopy Growth Corporation (TSE:WEED) recently released its first-quarter results, showing revenues in line with analyst predictions and smaller-than-expected statutory losses. Despite these positive surprises in the Q1 results, analysts have lowered their average price target for the company by 13% to CA$2.02, suggesting increased …

KAMADA ($KMDA) Releases Q2 2026 Earnings

Kamada: Q2 Earnings Snapshot

Optimi Health Stock Slides 3.4% on August 11 — Is This Psychedelics Manufacturer Getting Interesting Again?

Optimi Health Corp. (CN: OPTI) shares dropped 3.4% on August 11, 2026, without a clear company-specific reason, highlighting the volatility of the psychedelics sector. The company, which manufactures pharmaceutical-grade psilocybin and MDMA, has achieved operational milestones including production runs, product launches, and an export …

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts

BioAge Labs, Inc. (NASDAQ:BIOA) has received a "Moderate Buy" consensus rating from analysts, with six out of seven recommending a buy and one a sell. The average 12-month price target is $36.57, though recent targets vary from $21 to $40. The company reported a …

Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to "Hold" Rating

Zacks Research has upgraded Prestige Consumer Healthcare (NYSE:PBH) from a "strong sell" to a "hold" rating. This upgrade comes after the company exceeded quarterly earnings expectations, reporting $0.98 EPS against a $0.89 consensus and revenue of $265.71 million, a 6.5% increase year-over-year. The consensus …

Kamada Reports Record-High First Half and Second Quarter

Kamada Ltd. announced record-high financial results for the first half and second quarter of 2026, with double-digit growth in revenues and Adjusted EBITDA. The company reported first-half revenues of $100.2 million and Adjusted EBITDA of $25.7 million, and affirmed its 2026 annual guidance. This …

Kamada Announces Planned Transition of Chief Financial Officer

Kamada Ltd. announced that its Chief Financial Officer, Chaime Orlev, will transition out of his role effective December 31, 2026, to pursue other opportunities. Orlev has served as CFO since 2017 and will assist in the transition to his successor, for whom a search …

Kamada CFO Chaime Orlev to Exit Role After Nine Years

Kamada (NASDAQ: KMDA) announced that its Chief Financial Officer, Chaime Orlev, will step down on December 31, 2026, after nine years in the role, to pursue other opportunities. The company has initiated a search for his successor, and Orlev will provide transitional support. Kamada's …

Kamada reports record H1 revenues of $100.2M, up 13% YoY By Investing.com

Kamada Ltd. reported record first-half 2026 revenues of $100.2 million, marking a 13% increase year-over-year, driven by strong sales of KEDRAB, VARIZIG, and HEPAGAM. The biopharmaceutical company also announced a new three-year, $50 million plasma supply agreement and reaffirmed its annual revenue and adjusted …

Kamada (KMDA) delivers record H1 2026 growth and reaffirms double-digit 2026 guidance

Kamada Ltd. reported record financial results for the first half of 2026, with revenues of $100.2 million and adjusted EBITDA of $25.7 million, representing significant year-over-year growth. The company reaffirmed its full-year 2026 guidance for revenues between $200-$205 million and adjusted EBITDA of $50-$53 …

Kamada Secures 3-Year, ~$50M Plasma Deal; Sales Expected Q4

Liquidia Corp 2026: Revenue $171.68M, EPS $0.74— 10-Q Summary

Liquidia Corp reported strong financial results for the quarter ended 2026, with revenue reaching $171.68 million and diluted EPS of $0.74. This significant growth, representing an 1842.7% increase in revenue and 251% increase in diluted EPS year-over-year, was primarily driven by the successful commercial …

HC Wainwright Brokers Reduce Earnings Estimates for ETON

HC Wainwright has reduced its earnings per share estimates for Eton Pharmaceuticals (NASDAQ:ETON) for Q2 2026 and the full fiscal year 2026, lowering the Q2 estimate to $0.11 from $0.15 and the FY2026 estimate to $0.52, significantly below the broader consensus of $0.75. Despite …